+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Digital Biomarkers Market Size, Share & Trends Analysis Report by Type (Wearable, Mobile based Applications, Sensors), by Clinical Practice, by Therapeutic Area, by End-use, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 150 Pages
  • October 2022
  • Region: Global
  • Grand View Research
  • ID: 5681749

Quick Summary:

Breakthroughs in digital technology have given birth to a rapidly evolving market for digital biomarkers, a transformative tool in healthcare that is set to redefine patient care and pharmaceutical research alike. Digital biomarkers harness remote data collection technologies, wearable and mobile tech, and the internet to provide insights on health and wellness that go far beyond what traditional methods have offered. The application of these digital tools augments capabilities of healthcare systems, enabling early intervention and expedited identification of physical or mental illnesses.

Among the emerging trends, vocal digital biomarkers present remarkable growth potential. These innovative tools enable easy data gathering through voice recordings and personal tech devices such as cell phones and wearables. Furthermore, the escalating prevalence of chronic and neurodegenerative diseases is expected to fuel an undeniably compelling demand for enhanced drug development. Compared to conventional clinical trials, digital biomarkers can significantly accelerate the creation of new therapeutics, marking a monumental shift in pharmaceutical research and development.

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market's expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company’s position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights

  • Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate
  • Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period
  • Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period
  • Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies
  • North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period
  • By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Digital Biomarkers Market

What is the estimated value of the Global Digital Biomarkers Market?

The Global Digital Biomarkers Market was estimated to be valued at $2871.98 Million in 2022.

What is the growth rate of the Global Digital Biomarkers Market?

The growth rate of the Global Digital Biomarkers Market is 21.9%, with an estimated value of $13966.16 Million by 2030.

What is the forecasted size of the Global Digital Biomarkers Market?

The Global Digital Biomarkers Market is estimated to be worth $13966.16 Million by 2030.

Who are the key companies in the Global Digital Biomarkers Market?

Key companies in the Global Digital Biomarkers Market include Actigraph LLC, Alivecor Inc, Koneksa, Amgen Inc., Biogen Inc., Altoida Inc, Ixico plc, Adherium Limited, Empatica Inc and Huma.

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Digital BiomarkersMarket Summary, 2021
Chapter 3 Digital Biomarkers Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Digital Biomarkers Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
3.3.1.3 Expanding Therapeutic Area Application
3.3.1.4 Increasing Investment in Decentralized Clinical Trials
3.3.2 Market Restraints Analysis
3.3.2.1 Concerns about Data Privacy
3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
3.4 Digital Biomarkers Market Analysis Tools: Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Threat Of Substitutes
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 Pestel Analysis
3.5.1 Political & Legal Landscape
3.5.2 Social Landscape
3.5.3 Technology Landscape
3.5.4 Environmental Analysis
3.6 Regulatory Framework
3.7 Technology Overview
3.8 Pricing Analysis
3.9 Covid-19 Impact Analysis
3.9.1 Current And Future Impact Analysis
3.9.2 Impact Of Covid-19 On Market Players
Chapter 4 Competitive Landscape
4.1 Market participation categorization
4.2 Public Companies
4.2.1 Company Market Position Analysis
4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
4.3 Detailed list of market players
Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)
5.1 Type Movement Analysis, 2021 & 2030
5.1.1 Wearable
5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.2 Mobile Based Applications
5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.3 Sensors
5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
5.1.4 Others
5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)
6.1 Clinical Practice Movement Analysis, 2021 & 2030
6.1.1 Diagnostic Digital Biomarkers
6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.2 Monitoring Digital Biomarkers
6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.3 Predictive and Prognostic Digital Biomarkers
6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)
7.1 Therapeutic Area Movement Analysis, 2021 & 2030
7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.2 Respiratory Disorders
7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.3 Psychiatric Disorders
7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.4 Sleep & Movement Disease
7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.5 Neurological Disorders
7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.6 Musculoskeletal Disorders
7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
7.1.7 Others
7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)
8.1 End-Use Movement Analysis, 2021 & 2030
8.1.1 Healthcare Companies
8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.2 Healthcare Providers
8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
8.1.3 Payers
8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
8.1.4 Others
8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)
9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
9.2 North America
9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.2 U.S.
9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.2.3 Canada
9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
9.3 Europe
9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.2 U.K.
9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.3 Germany
9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.4 Netherlands
9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.5 Italy
9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.3.6 Switzerland
9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.2 Japan
9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.3 China
9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.4 Australia
9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.5 India
9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.4.6 South Korea
9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5 Latin America
9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.2 Brazil
9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.5.3 Mexico
9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6 MEA
9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.2 South Africa
9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
9.6.3 Israel
9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
Chapter 10 Company Profiles
10.1 ActiGraph LLC
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 AliveCor Inc
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.2.4 Strategic Initiatives
10.3 Koneksa
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Product Benchmarking
10.3.4 Strategic Initiatives
10.4 Amgen Inc.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Product Benchmarking
10.4.4 Strategic Initiatives
10.5 Biogen Inc.
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 Altoida Inc
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 Strategic Initiatives
10.7 IXICO plc
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Product Benchmarking
10.7.4 Strategic Initiatives
10.8 Adherium Limited
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Product Benchmarking
10.8.4 Strategic Initiatives
10.9 Empatica Inc
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.9.4 Strategic Initiatives
10.10 Huma
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Product Benchmarking
10.10.4 Strategic Initiatives
10.11 VivoSense
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Product Benchmarking
10.11.4 Strategic Initiatives
10.12 ResApp (Pfizer)
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Product Benchmarking
10.12.4 Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of key companies
Table 3. North America Digital Biomarkers market, by country, 2017-2030 (USD Million)
Table 4. North America Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 5. North America Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 6. North America Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 7. North America Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 8. U.S. Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 9. U.S. Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 10. U.S. Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 11. U.S. Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 12. Canada Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 13. Canada Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 14. Canada Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 15. Canada Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 16. Europe Digital Biomarkers market, by country, 2017-2030 (USD Million)
Table 17. Europe Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 18. Europe Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 19. Europe Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 20. Europe Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 21. U.K. Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 22. U.K. Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 23. U.K. Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 24. U.K. Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 25. Germany Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 26. Germany Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 27. Germany Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 28. Germany Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 29. Netherlands Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 30. Netherlands Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 31. Netherlands Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 32. Netherlands Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 33. Italy Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 34. Italy Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 35. Italy Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 36. Italy Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 37. Switzerland Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 38. Switzerland Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 39. Switzerland Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 40. Switzerland Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 41. Asia Pacific Digital Biomarkers market, by country, 2017-2030 (USD Million)
Table 42. Asia Pacific Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 43. Asia Pacific Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 44. Asia Pacific Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 45. Asia Pacific Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 46. China Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 47. China Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 48. China Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 49. China Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 50. Japan Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 51. Japan Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 52. Japan Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 53. Japan Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 54. India Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 55. India Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 56. India Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 57. India Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 58. Australia Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 59. Australia Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 60. Australia Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 61. Australia Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 62. South Korea Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 63. South Korea Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 64. South Korea Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 65. South Korea Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 66. LATAM Digital Biomarkers market, by country, 2017-2030 (USD Million)
Table 67. LATAM Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 68. LATAM Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 69. LATAM Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 70. LATAM Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 71. Brazil Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 72. Brazil Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 73. Brazil Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 74. Brazil Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 75. Mexico Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 76. Mexico Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 77. Mexico Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 78. Mexico Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 79. MEA Digital Biomarkers market, by country, 2017-2030 (USD Million)
Table 80. MEA Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 81. MEA Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 82. MEA Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 83. MEA Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 84. South Africa Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 85. South Africa Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 86. South Africa Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 87. South Africa Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 88. Israel Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 89. Israel Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 90. Israel Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 91. Israel Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
Table 92. Global Digital Biomarkers market, by region, 2017-2030 (USD Million)
Table 93. Global Digital Biomarkers market, by type, 2017-2030 (USD Million)
Table 94. Global Digital Biomarkers market, by clinical practice, 2017-2030 (USD Million)
Table 95. Global Digital Biomarkers market, by therapeutic area, 2017-2030 (USD Million)
Table 96. Global Digital Biomarkers market, by end-use, 2017-2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD Modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Commodity flow analysis
Fig. 10 Segment-Based Penetration Model
Fig. 11 Market summary (2021, Million)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Market variable analysis
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Digital Biomarkers Market: By Type Movement Analysis, 2021 & 2030
Fig. 17 Wearable Market, 2017-2030 (Million)
Fig. 18 Mobile based Applications Market, 2017-2030 (Million)
Fig. 19 Sensors Market, 2017-2030 (Million)
Fig. 20 Others Market, 2017-2030 (Million)
Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis, 2021 & 2030
Fig. 22 Diagnostic digital biomarkers market, 2017-2030 (Million)
Fig. 23 Monitoring digital biomarkers market, 2017-2030 (Million)
Fig. 24 Predictive and Prognostic digital biomarkers market, 2017-2030 (Million)
Fig. 25 Others digital biomarker market, 2017-2030 (Million)
Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis, 2021 & 2030
Fig. 27 Cardiovascular and metabolic disorders (CVMD) market, 2017-2030 (Million)
Fig. 28 Respiratory disorders market, 2017-2030 (Million)
Fig. 29 Psychiatric disorders market, 2017-2030 (Million)
Fig. 30 Sleep & movement disease market, 2017-2030 (Million)
Fig. 31 Neurological disorders market, 2017-2030 (Million)
Fig. 32 Musculoskeletal disorders market, 2017-2030 (Million)
Fig. 33 Others market, 2017-2030 (Million)
Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis, 2021 & 2030
Fig. 35 Healthcare companies market, 2017-2030 (Million)
Fig. 36 Healthcare Providers market, 2017-2030 (Million)
Fig. 37 Payers market, 2017-2030 (Million)
Fig. 38 Others market, 2017-2030 (Million)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 Regional outlook, 2021 & 2030
Fig. 41 North America Digital Biomarkers Market, 2017-2030 (Million)
Fig. 42 U.S. Digital Biomarkers Market, 2017-2030 (Million)
Fig. 43 Canada Digital Biomarkers Market, 2017-2030 (Million)
Fig. 44 Europe Digital Biomarkers Market, 2017-2030 (Million)
Fig. 45 U.K. Digital Biomarkers Market, 2017-2030 (Million)
Fig. 46 Germany Digital Biomarkers Market, 2017-2030 (Million)
Fig. 47 Netherlands Digital Biomarkers Market, 2017-2030 (Million)
Fig. 48 Italy Digital Biomarkers Market, 2017-2030 (Million)
Fig. 49 Switzerland Digital Biomarkers Market, 2017-2030 (Million)
Fig. 50 Asia Pacific Digital Biomarkers Market, 2017-2030 (Million)
Fig. 51 Japan Digital Biomarkers Market, 2017-2030 (Million)
Fig. 52 China Digital Biomarkers Market, 2017-2030 (Million)
Fig. 53 India Digital Biomarkers Market, 2017- 2030 (Million)
Fig. 54 South Korea Digital Biomarkers Market, 2017-2030 (Million)
Fig. 55 Australia Digital Biomarkers Market, 2017-2030 (Million)
Fig. 56 Latin America Digital Biomarkers Market, 2017-2030 (Million)
Fig. 57 Brazil Digital Biomarkers Market, 2017-2030 (Million)
Fig. 58 Mexico Digital Biomarkers Market, 2017-2030 (Million)
Fig. 59 MEA Digital Biomarkers Market, 2017-2030 (Million)
Fig. 60 South Africa Digital Biomarkers Market, 2017-2030 (Million)
Fig. 61 Israel Digital Biomarkers Market, 2017-2030 (Million)
Fig. 62 Market Participation Categorization
Fig. 63 Company market position analysis

Companies Mentioned

  • Actigraph LLC
  • Alivecor Inc
  • Koneksa
  • Amgen Inc.
  • Biogen Inc.
  • Altoida Inc
  • Ixico plc
  • Adherium Limited
  • Empatica Inc
  • Huma
  • Vivosense
  • Resapp (Pfizer)

Methodology

Loading
LOADING...